3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
1
Sleep Initiation and Maintenance Disorders
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Depression
1
Chronic Pain
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anxiety Disorders
1
Interventions
Oxaliplatin
3
Irinotecan
3
Surveys and Questionnaires
2
Specimen Handling
2
Radiosurgery
2
Leucovorin
2
Ketamine
2
Hydroxychloroquine
2
Fluorouracil
2
Capecitabine
2
ulixertinib
1
tegafur-gimeracil-oteracil
1
regorafenib
1
pazopanib
1
lanreotide
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
dolasetron
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
danvatirsen
1
cobimetinib
1
brivanib
1
auricularum
1
atezolizumab
1
alectinib
1
aldesleukin
1
abelacimab
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Neoplasms
×
Cognitive Behavioral Therapy
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled